Duloxetine significantly reduced the number of weekly incontinence episodes among women with stress urinary incontinence, according to a phase III study published in the Journal of Urology. Additionally, women on duloxetine experienced significant improvements in quality of life measures, when compared with women taking placebo.
Eli Lilly and Company and Boehringer Ingelheim signed a long-term agreement in November 2002, to jointly develop and commercialize duloxetine hydrochloride. Duloxetine is currently being developed for the treatment of stress urinary incontinence (SUI) and depression.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment